Vesper Ventures SA
VC Fund
Florianópolis, Brazil
Vesper Ventures SA is a VC fund in Florianópolis focused on Biotechnology and Genetics. Vesper is a venture building company with focus on biotech's. Our mission is to help passionate and talented scientists, entrepreneurs and visionaries transform innovative ideas into great companies.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Vesper Ventures SA invests in
Stages Vesper Ventures SA invests in
Countries Vesper Ventures SA invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Seed
- $200k–$4.5M
Investment Focus
Industry
- Biotechnology 8 (80%)
- Genetics 3 (30%)
- Agriculture 2 (20%)
- Organic 1 (10%)
- Life Science 1 (10%)
Stage
- Pre-Seed 5 (50%)
- Seed 3 (30%)
- Venture - Series Unknown 1 (10%)
Country
- Brazil 6 (60%)
- United States 2 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Gabriel Mantovani Bottós
Co-Founder, CEO, and Senior Partner
|
Co-Founder, CEO, and Senior Partner | Total investments: 0 | Find email | |
Rafael Mantovani Bottós
Co-Founder
|
Co-Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Vyro Bio
|
Vyro is an immuno-oncology (I-O) biotechnology company developing cancer-killing, or ‘oncolytic’, viruses (OVs) designed to target adult and pediatric central nervous system (CNS) tumors, based on pioneering research and breakthrough discovery of the oncolytic properties of the Zika Virus (ZIKV). | $200K / Seed / Jan 01, 2025 | |
Symbiomics
|
Symbiomics provides the next-generation biologicals based on robust-colonizing microbes for plant growth improvement through sequencing technologies, machine learning, and genome editing tools. | Venture - Series Unknown / Dec 14, 2023 | |
HapiSeeds
|
HapiSeeds develops new technologies aimed at Sustainable Agriculture, increasing food production through environmentally friendly practices. These technologies involve the development of new commercial plant varieties, either through plant engineering with genome editing or by assisting plant breeders and farmers with molecular tools to achieve:increased biomass and plant productivity; reduced use of chemical fertilizers through innovative cultivation technologies (bioinoculants); lower irrigation requirements; higher yield per cultivated area; and reduced pesticide use by enhancing disease resistance. | Pre-Seed / Dec 01, 2023 | |
Cellertz Bio
|
Cellertz Bio is a biotech company. Their integrated in silico and experimental approach is designed to generate the next generation of cell therapies against cancer and other diseases by precisely controlling gene regulatory networks defining cell behaviors. Their goal is to determine which genes to control to achieve their cell therapy goals | Pre-Seed / Mar 01, 2023 | |
|
Symbiomics
|
Symbiomics provides the next-generation biologicals based on robust-colonizing microbes for plant growth improvement through sequencing technologies, machine learning, and genome editing tools. | Pre-Seed / Mar 07, 2022 | |
InEdita Bio
|
InEdita’s nature-inspired, non-transgenic, genome-edited crop varieties reduce the use of chemical pesticides in food productionBy changing the genetic code encrypted in a text with millions of messages resulting from the combination of four letters (A, C, G, and T), InEdita Bio creates plants resistant to pests and diseases and enhanced waterand nutrient use efficiency. | Pre-Seed / Mar 01, 2022 | |
|
Vyro Bio
|
Vyro is an immuno-oncology (I-O) biotechnology company developing cancer-killing, or ‘oncolytic’, viruses (OVs) designed to target adult and pediatric central nervous system (CNS) tumors, based on pioneering research and breakthrough discovery of the oncolytic properties of the Zika Virus (ZIKV). | $1.5M / Seed / Feb 19, 2022 | |
FUTR BIO
|
FUTR BIO is a biotechnology company that aims to prevent and cure diseases such as infections and cancer. They focused on developing mRNA vaccines. They developed mRNA vaccine technologies to induce immune responses by fine-tuning control of the mammalian immune system. | Pre-Seed / Feb 12, 2022 | |
Reddot.bio
|
Reddot.bio is a biotech company that provides an unique and powerful diagnostic platform to accurately identify genetic traces | Seed / Jan 01, 2022 | |
Aptah Bio
|
Imagine a world where age-related diseases are things of the past! That’s the potential Aptah Bio is unlocking. We are working with leading global scientists, laboratories, and the best patent attorneys to develop the next pharmaceutical blockbuster with a multi-billion dollar market value, able to impact the lives of millions of people.AptahBio’s compound significantly reduces age-related random RNA processing errors, thus eliminating multiple faulty RNAs and resulting toxic proteins with one compound. Its utility spans across multiple therapeutic categories, including age-related neurodegenerative diseases and cancer, areas of high unmet medical need, and significant commercial potential. As the global population ages, age-related diseases have become a significant, growing concern and socioeconomic burden, currently inadequately addressed by existing therapies.Our therapy holds the potential to address the root cause of many of these age-related dysfunctional proteins and the diseases they cause. | $4.5M / Seed / Jan 20, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Vesper Ventures SA invest in?
Vesper Ventures SA invests primarily in Biotechnology, Genetics and Agriculture startups, most often at Pre-Seed and Seed stage. Most of the 10 investments tracked by Shizune back companies in Brazil. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Vesper Ventures SA's check size?
Vesper Ventures SA typically joins rounds of $200k–$4.5M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Vesper Ventures SA participates in.
How do I contact Vesper Ventures SA?
Public channels for Vesper Ventures SA include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Vesper Ventures SA?
The team at Vesper Ventures SA includes Gabriel Mantovani Bottós (Co-Founder, CEO, and Senior Partner) and Rafael Mantovani Bottós (Co-Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
